Brief: Titan Pharmaceuticals Inc - Announced A Strategic Restructuring

Titan Pharmaceuticals

15/10/2020 13:44

Oct 15 (Reuters) - Titan Pharmaceuticals Inc  TTNP.O :
    * TITAN PHARMACEUTICALS INC - ANNOUNCED A STRATEGIC
RESTRUCTURING
    * TITAN PHARMACEUTICALS INC - RESTRUCTURE COMPANY TO FOCUS
ON
PRONEURA(®)-BASED PRODUCT DEVELOPMENT
    * TITAN PHARMACEUTICALS INC - DISCONTINUE ITS U.S.
PROBUPHINE(®)
(BUPRENORPHINE) IMPLANT SALES AND WIND DOWN PROBUPHINE
COMMERCIALIZATION ACTIVITIES;
    * TITAN PHARMACEUTICALS - PLANS TO COMPLETE NEGOTIATIONS
WITH ITS
LENDERS TO ELIMINATE OUTSTANDING DEBT
    * TITAN PHARMACEUTICALS INC - DETERMINED TO WIND DOWN ITS
U.S.
PROBUPHINE BUSINESS
    * TITAN PHARMACEUTICALS - HAVE BEGUN EXPLORING FEASIBILITY
OF
USING JT-09 PRONEURA IMPLANTS IN TREATMENT OF PRURITUS
    * TITAN PHARMACEUTICALS - CURRENT EXECUTIVE CHAIRMAN, MARC
RUBIN
WILL ASSUME POSITION OF CHAIRMAN AND CEO
    * TITAN PHARMACEUTICALS - WINDING DOWN OF COMMERCIAL
OPERATIONS TO
RESULT IN A LOWER OPERATING CASH BURN MOVING FORWARD
    * TITAN PHARMA - OPEN TO EVALUATING REASONABLE OFFERS FROM
INTERESTED THIRD-PARTIES TO CONTINUE MAKING PROBUPHINE
COMMERCIALLY AVAILABLE IN U.S.

Source text for Eikon:  ID:nPn2t5BPwa 
Further company coverage:  TTNP.O 

 (((Reuters.Briefs@thomsonreuters.com);))